Sulphate conjugation of p‐hydroxytriamterene by platelet phenol sulphotransferase: assay conditions and correlation with metabolism in man.

1 Sulphate conjugation catalyzed by phenol sulphotransferase (PST) is an important pathway in the metabolism of many drugs including triamterene. Variations in PST activity in an easily obtained tissue such as the platelet might reflect individual differences in the sulphate conjugation in other organs and tissues. Human platelets contain at least two forms of PST, a thermolabile (TL) form for which dopamine is a substrate and a thermostable (TS) form for which low concentrations of p‐nitrophenol serve as a substrate. 2 p‐OH‐ triamterene, the major metabolite of triamterene, is conjugated with sulphate in vivo. p‐OH‐triamterene was a substrate for platelet PST with an apparent Michaelis‐Menten value of 26 microM. Thermal stability studies indicated that p‐OH‐triamterene was a substrate for only the TS form of platelet PST. 3 When platelet homogenates from 29 individual subjects were tested, there was a significant correlation between PST activities measured with 4 microM p‐nitrophenol and with p‐OH‐ triamterene (r = 0.985, P less than 0.0001) but not between activities measured with dopamine and with p‐OH‐triamterene (r = 0.023, P greater than 0.2). These results confirmed that p‐OH‐triamterene was a substrate for only the TS form of human platelet PST. 4 The same 29 subjects were treated with 1 mg/kg of triamterene orally. 24‐h urinary excretions of triamterene, p‐OH‐triamterene and p‐OH‐triamterene sulphate averaged 15.3%, 6.3% and 78.4%, respectively, of the total of triamterene plus measured metabolites excreted. The excretion of triamterene plus the two metabolites averaged 43.1 +/‐ 2.6% (mean +/‐ s.e. mean) of the ingested dose. There was not a significant correlation between the proportion of p‐OH‐triamterene excreted as sulphate conjugate and the activities of either the TS or TL forms of platelet PST activity. 1983 The British Pharmacological Society